Use of antiviral drugs for seasonal influenza: Foundation document for practitioners—Update 2019

Aoki, Fred Y.; Allen, Upton; Mubareka, Samira; Papenburg, Jesse; Stiver, H Grant; Evans, Gerald A.

doi:10.3138/jammi.2019.02.08

Cited by 6 publications

(11 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Canada Foundation guidance document (27), new data on the effectiveness of oseltamivir have been published, further supporting use of oral oseltamivir as the primary agent in Canada for treatment of suspected or confirmed influenza.…”

Section: Since the Publication Of The Updated 2019 Association Of Medmentioning

confidence: 97%

“…Please refer to the AMMI Canada Foundation document (27) for details on dosing regimens. The standard adult dose of oseltamivir is 75 mg by mouth twice a day.…”

Section: Antiviral Dosage Regimensmentioning

confidence: 99%

“…Dosing should be adjusted according to degree of renal impairment. Oseltamivir dosing regimens for patients with renal impairment are detailed in Table 3 of the Foundation document (27).…”

Section: Antiviral Dosage Regimensmentioning

confidence: 99%

“…Guidance on the use of chemoprophylaxis to protect individuals against influenza was published in the AMMI Foundation document (27) and continues to be appropriate (Appendix D). Early empiric presumptive therapy continues to be recommended in preference to post-exposure prophylaxis.…”

Section: Antiviral Prophylaxismentioning

confidence: 99%

See 3 more Smart Citations

2020–2021 AMMI Canada guidance on the use of antiviral drugs for influenza in the setting of co-circulation of seasonal influenza and SARS-CoV-2 viruses in Canada

Mubareka

Aoki

Allen

et al. 2020

Official Journal of the Association of Medical Microbiology and

Self Cite

View full text Add to dashboard Cite

We provide an update to the Association of Medical Microbiology and Infectious Disease Canada foundation guidance for the upcoming 2020–2021 influenza season in Canada. Important issues for this year include the implications of co-circulation of SARS-CoV-2, the role of diagnostic testing, and a restatement of dosing and administration recommendations for neuraminidase inhibitors in various age groups and underlying health conditions. Although peramivir and baloxivir are now licensed in Canada, neither is currently marketed, so this guidance focuses on further optimizing the use of oseltamivir and zanamivir.

show abstract

Section: Since the Publication Of The Updated 2019 Association Of Medmentioning

confidence: 97%

“…Please refer to the AMMI Canada Foundation document (27) for details on dosing regimens. The standard adult dose of oseltamivir is 75 mg by mouth twice a day.…”

Section: Antiviral Dosage Regimensmentioning

confidence: 99%

“…Dosing should be adjusted according to degree of renal impairment. Oseltamivir dosing regimens for patients with renal impairment are detailed in Table 3 of the Foundation document (27).…”

Section: Antiviral Dosage Regimensmentioning

confidence: 99%

Section: Antiviral Prophylaxismentioning

confidence: 99%

See 2 more Smart Citations

2020–2021 AMMI Canada guidance on the use of antiviral drugs for influenza in the setting of co-circulation of seasonal influenza and SARS-CoV-2 viruses in Canada

Mubareka

Aoki

Allen

et al. 2020

Official Journal of the Association of Medical Microbiology and

Self Cite

View full text Add to dashboard Cite

show abstract

“…This and related issues are addressed in this document. Additional details on influenza antiviral drug recommendations can be found in the AMMI Canada foundation document on the use of antiviral drugs for seasonal influenza (2).…”

mentioning

confidence: 99%

Guidance on the use of antiviral agents for the 2019–2020 influenza season

Papenburg

Mubareka

Allen

et al. 2020

Official Journal of the Association of Medical Microbiology and

Self Cite

View full text Add to dashboard Cite

Efficient symptomatic treatment and viral load reduction for children with influenza virus infection by nasal-spraying Bacillus spore probiotics

Tran,

Phung,

Tran

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Influenza virus is a main cause of acute respiratory tract infections (ARTIs) in children. This is the first double-blind, randomized, and controlled clinical trial examining the efficacy of nasal-spraying probiotic LiveSpo Navax, which contains 5 billion of Bacillus subtilis and B. clausii spores in 5 mL, in supporting treatment of influenza viral infection in pediatric patients. We found that the nasal-spraying Bacillus spores significantly shortened the recovery period and overall treatment by 2 days and increased treatment effectiveness by 58% in resolving all ARTIs’ symptoms. At day 2, the concentrations of influenza virus and co-infected bacteria were reduced by 417 and 1152 folds. Additionally, the levels of pro-inflammatory cytokines IL-8, TNF-α, and IL-6 in nasopharyngeal samples were reduced by 1.1, 3.7, and 53.9 folds, respectively. Compared to the standard control group, treatment regimen with LiveSpo Navax demonstrated significantly greater effectiveness, resulting in 26-fold reduction in viral load, 65-fold reduction in bacterial concentration, and 1.1–9.5-fold decrease in cytokine levels. Overall, nasal-spraying Bacillus spores can support the symptomatic treatment of influenza virus-induced ARTIs quickly, efficiently and could be used as a cost-effective supportive treatment for respiratory viral infection in general.Clinical trial registration no: NCT05378022 on 17/05/2022.

show abstract

Use of antiviral drugs for seasonal influenza: Foundation document for practitioners—Update 2019

Abstract: This document updates the previous AMMI Canada Foundation Guidance (2013) on the use of antiviral therapy for influenza.

Cited by 6 publications

References 131 publications

2020–2021 AMMI Canada guidance on the use of antiviral drugs for influenza in the setting of co-circulation of seasonal influenza and SARS-CoV-2 viruses in Canada

2020–2021 AMMI Canada guidance on the use of antiviral drugs for influenza in the setting of co-circulation of seasonal influenza and SARS-CoV-2 viruses in Canada

Guidance on the use of antiviral agents for the 2019–2020 influenza season

Efficient symptomatic treatment and viral load reduction for children with influenza virus infection by nasal-spraying Bacillus spore probiotics

Contact Info

Product

Resources

About